DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07055607

PILLAR

Enrolling by invitation

A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice

Lead sponsor

Novo Nordisk A/S

Asset

Semaglutide

GLP-1 agonist

Listed sites

30

Recruiting sites

—

Enrollment

1,250

estimated

Study population

Obesity / overweight

Key I/E criterion

—

Primary endpoints

•Body weight, absolute change (kg)•Body weight, % change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07055607
Org study IDNN9536-8189
Secondary IDU1111-1308-1428World Health Organization (WHO)

Timeline

Milestones

Study start2025-05-01actual
Study first posted2025-07-09actual
Last update posted2026-05-14actual
Primary completion2028-08-15estimated
Study completion2028-08-15estimated

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

Participants will be treated with Wegovy according to the local labels in Spain, Switzerland and the United Kingdom (UK).

Inclusion criteria

•Signed consent obtained before any study-related activities (study-related activities are any pro-cedure related to recording of data according to the protocol).
•Are eligible for Wegovy and are due to initiate treatment for the first time within the study period; the decision to initiate treatment with commercially available Wegovy has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
•Male or female, age above or equal to 18 years at time of signing informed consent.
•Have at least one reported weight measurement documented at baseline or within 28 days prior to baseline.
•Participants must be able to complete the electronic patient reported outcome (ePRO) questionnaires on a compatible electronic device with internet access.
•Fulfil the respective reimbursement criteria in the visit prior to / at baseline in Switzerland and United Kingdom (UK).

Exclusion criteria

•Previous participation in this study. Participation is defined as having given informed consent in this study.
•Presence of a documented refusal or unwillingness to participate in research.
•Previous treatment with other obesity management pharmacotherapy or any glucagon like pep-tide-1 (GLP- 1) receptor agonist up to 90 days prior to baseline in Switzerland and UK.
•Previous treatment with other obesity management pharmacotherapy or any GLP- 1 receptor agonist up to 30 days prior to baseline in Spain.
•Pregnant or women of childbearing potential and not using a highly effective contraceptive method.
•Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation with the study requirements.
•Individuals who have reported plans to move out in the next 12 months to an area not serviced by their current site.
•Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) in Spain and UK.
•Participant has had a prior serious allergic reaction to semaglutide or any of the ingredients in Wegovy.
•Have had Saxenda reimbursed by basic mandatory health insurance for a cumulative period of more than 12 months prior to baseline in Switzerland.
•Documented history of diabetes mellitus type 1 and type 2 in Spain.
•Presence of diabetic complications and/or at risk of hypoglycaemia (with a documented history of frequent hypoglycaemia) in Spain.

Endpoints (47)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
13
Cardiometabolic biomarkers
11
Safety / tolerability / PK
8
Patient-reported / QoL
7
Other (unclassified)
5
Other clinical outcomes
2
Glycemic / diabetes
1

Weight & body composition

13 endpoints
Primary/protocol endpoint

Absolute change in body weight (kilograms [kg])

Time frame:From baseline (0 months) to the end of observation (24 months)

Body weight, absolute change (kg)

change from baseline, improvement

Primary/protocol endpoint

Percentage change in body weight (percentage [%])

Time frame:From baseline (0 months) to the end of observation (24 months)

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Absolute change in waist circumference (centimeters [cm])

Time frame:From baseline (0 months) to the end of observation (24 months)

Waist circumference, change

change from baseline, improvement

Secondary/protocol endpoint

Absolute change in waist-to-height ratio

Time frame:From baseline (0 months) to the end of observation (24 months)

change from baseline, improvement

Secondary/protocol endpoint

Percentage change in waist circumference (%)

Time frame:From baseline (0 months) to the end of observation (24 months)

Waist circumference, change

percent change from baseline, improvement

Secondary/protocol endpoint

Number of participants who achieve greater than or equal to (>=) 5 percent body weight reduction (Yes/No)

Time frame:From baseline (0 months) to the end of observation (24 months)

≥5% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

For Switzerland: Number of participants who achieve >=7 percent body weight reduction (Yes/No)

Time frame:From baseline (0 months) to the end of observation (22 months)

threshold achievement, improvement

Secondary/protocol endpoint

Number of participants who achieve >=10 percent body weight reduction (Yes/No)

Time frame:From baseline (0 months) to the end of observation (24 months)

≥10% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

For Switzerland: Number of participants who achieve >=12 percent body weight reduction (Yes/No)

Time frame:From baseline (0 months) to the end of observation (22 months)

threshold achievement, improvement

Secondary/protocol endpoint

Number of participants who achieve >=15 percent body weight reduction (Yes/No)

Time frame:From baseline (0 months) to the end of observation (24 months)

≥15% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Number of participants who achieve >=20 percent body weight reduction (Yes/No)

Time frame:From baseline (0 months) to the end of observation (24 months)

≥20% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Change in percentage of participant in each Body Mass Index (BMI) category

Time frame:From baseline (0 months) to the end of observation (24 months)

categorical status, improvement

Secondary/protocol endpoint

For Switzerland: Change in percentage of participants fulfilling the necessary weight loss reimbursement criteria

Time frame:From baseline (0 months) to the end of observation (22 months)

threshold achievement, improvement

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

Change in Glycated Haemoglobin (HbA1c) (%)

Time frame:From baseline (0 months) to the end of observation (24 months)

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Cardiometabolic biomarkers

11 endpoints
Secondary/protocol endpoint

Change in High Density Lipoprotein (HDL) Cholesterol (milligrams per decilitre [mg/dL])

Time frame:From baseline (0 months) to the end of observation (24 months)

HDL-C, change

change from baseline, improvement

LOINC 2085-9

Secondary/protocol endpoint

Change in HDL Cholesterol (millimoles per litre [mmol/L])

Time frame:From baseline (0 months) to the end of observation (24 months)

HDL-C, change

change from baseline, improvement

LOINC 2085-9

Secondary/protocol endpoint

Change in Low Density Lipoprotein (LDL) Cholesterol (mg/dL)

Time frame:From baseline (0 months) to the end of observation (24 months)

LDL-C, change

change from baseline, improvement

LOINC 13457-7

Secondary/protocol endpoint

Change in LDL Cholesterol (mmol/L)

Time frame:From baseline (0 months) to the end of observation (24 months)

LDL-C, change

change from baseline, improvement

LOINC 13457-7

Secondary/protocol endpoint

Change in Very Low Density Lipoprotein (VLDL) Cholesterol (mg/dL)

Time frame:From baseline (0 months) to the end of observation (24 months)

VLDL, change

change from baseline, improvement

Secondary/protocol endpoint

Change in VLDL Cholesterol (mmol/L)

Time frame:From baseline (0 months) to the end of observation (24 months)

VLDL, change

change from baseline, improvement

Secondary/protocol endpoint

Change in Free Fatty Acid (FFA) (mmol/L)

Time frame:From baseline (0 months) to the end of observation (24 months)

Free fatty acids, change

change from baseline, improvement

Secondary/protocol endpoint

Change in Triglycerides (mg/dL)

Time frame:From baseline (0 months) to the end of observation (24 months)

Triglycerides, change

change from baseline, improvement

LOINC 2571-8

Secondary/protocol endpoint

Change in Triglycerides (mmol/L)

Time frame:From baseline (0 months) to the end of observation (24 months)

Triglycerides, change

change from baseline, improvement

LOINC 2571-8

Secondary/protocol endpoint

Change in systolic blood pressure

Time frame:From baseline (0 months) to the end of observation (24 months)

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Secondary/protocol endpoint

Change in diastolic blood pressure

Time frame:From baseline (0 months) to the end of observation (24 months)

Diastolic BP, change

change from baseline, improvement

LOINC 8462-4

Patient-reported / QoL

7 endpoints
Secondary/protocol endpoint

Absolute change in the EuroQoL-5-Dimension (5-Level) (EQ-5D-5L)

Time frame:From baseline (0 months) to the end of observation (24 months)

EQ-5D index

change from baseline, improvement

Secondary/protocol endpoint

Absolute change in the EQ Visual Analogue Score (EQ-VAS)

Time frame:From baseline (0 months) to the end of observation (24 months)

EQ-5D VAS

change from baseline, improvement

Secondary/protocol endpoint

Absolute change in the Adelphi Adherence Questionnaire (ADAQ) score

Time frame:From baseline (0 months) to the end of observation (24 months)

change from baseline, improvement

Secondary/protocol endpoint

Absolute change in treatment satisfaction questionnaire for medication 9 (TSQM-9) domain scores

Time frame:From baseline (0 months) to the end of observation (24 months)

change from baseline, improvement

Secondary/protocol endpoint

Absolute change in percentage of work time missed (absenteeism) due to weight problem using Work Productivity and Activity Impairment Questionnaire (WPAI)

Time frame:From baseline (0 months) to the end of observation (24 months)

change from baseline, improvement

Secondary/protocol endpoint

Absolute change in percentage of time impaired while working (presenteeism) due to weight problem using WPAI

Time frame:From baseline (0 months) to the end of observation (24 months)

change from baseline, improvement

Secondary/protocol endpoint

Absolute change in percentage of activity impairment due to weight problem using WPAI

Time frame:From baseline (0 months) to the end of observation (24 months)

change from baseline, improvement

Safety / tolerability / PK

8 endpoints
Secondary/protocol endpoint/low confidence

Median time to Wegovy® maintenance dose

Time frame:From baseline to the date of reported maintenance dose during the observation period (24 months)

time to event, descriptive

Secondary/protocol endpoint

Median time to each Wegovy® dose escalation

Time frame:Date from the start of the previous dose to the date of each subsequent escalation during the observation period (24 months)

descriptive

Secondary/protocol endpoint

Maximum dose of Wegovy® for weight management

Time frame:After baseline to any given time during the observation period (24 months)

descriptive

Secondary/protocol endpoint

For UK and Spain: Change in percentage of participants on Wegovy® with each of drug-related adverse reaction

Time frame:From baseline (0 months) to the end of observation (24 months)

Treatment-emergent AEs (any)

descriptive

Secondary/protocol endpoint

Median persistence time of Wegovy® treatment

Time frame:From baseline (0 months) to the end of observation (24 months)

descriptive

Secondary/protocol endpoint

Change in percentage of participants who discontinued

Time frame:From baseline (0 months) to the end of observation (24 months)

percent change from baseline, event

Secondary/protocol endpoint

Percentage of participants who discontinued/withdrawn

Time frame:From baseline (0 months) to the end of observation (24 months)

Discontinuation due to AE

threshold achievement, event

Secondary/protocol endpoint

For Switzerland: Percentage of participants who stopped treatment (Yes/No)

Time frame:From baseline (0 months) to the end of observation (22 months)

Discontinuation due to AE

threshold achievement, event

Other clinical outcomes

2 endpoints
Secondary/protocol endpoint/low confidence

Percentage change in the prevalence of obesity-related conditions

Time frame:From baseline (0 months) to the end of observation (24 months)

percent change from baseline, improvement

Secondary/protocol endpoint

Percentage change in the usage of additional treatments for weight loss (Yes/No)

Time frame:From baseline (0 months) to the end of observation (24 months)

percent change from baseline, descriptive

Other (unclassified)

5 endpoints
Secondary/protocol endpoint/low confidence

Percentage change in the total daily dosage of concomitant drugs (Yes/No)

Time frame:From baseline (0 months) to the end of observation (24 months)

categorical status, descriptive

Secondary/protocol endpoint/low confidence

For Switzerland: Percentage of participants who continued under reimbursement by basic mandatory health insurance (Yes/No)

Time frame:From baseline (0 months) to the end of observation (22 months)

categorical status, descriptive

Secondary/protocol endpoint/low confidence

For Switzerland: Percentage of participants who switched to out-of-pocket payment (or any other arrangement) (Yes/No)

Time frame:From baseline (0 months) to the end of observation (22 months)

categorical status, descriptive

Secondary/protocol endpoint/low confidence

For Spain: Percentage of participants who have continued under out-of-pocket payment (Yes/No)

Time frame:From baseline (0 months) to the end of observation (12 months)

categorical status, descriptive

Secondary/protocol endpoint/low confidence

For Spain: Percentage of participants who have switched to reimbursement by the Public Health System (Yes/No)

Time frame:From baseline (0 months) to the end of observation (12 months)

categorical status, descriptive

Publications (9)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.